Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: PALOMA, an open-label, multicenter, dose escalation phase 1b study.

被引：2
|
作者：
Krebs, Matthew
Johnson, Melissa Lynne
Cho, Byoung Chul
Park, Keunchil
Haddish-Berhane, Nahor
Zemlickis, Donna
Mitselos, Anna
Meacle, Francis
Knoblauch, Roland Elmar
Hellemans, Peter
Minchom, Anna Rachel
机构：
[1] Univ Manchester, Fac Biol Med & Hlth, Div Canc Sci, Manchester, Lancs, England
[2] Manchester Acad Hlth Sci Ctr, Christie NHS Fdn Trust, Manchester, Lancs, England
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[6] Janssen R&D, Spring House, PA USA
[7] Janssen R&D, Toronto, ON, Canada
[8] Janssen R&D, Beerse, Belgium
[9] Royal Marsden Inst Canc Res, Drug Dev Unit, Sutton, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS3150
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3150
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: Initial safety and pharmacokinetic results from the PALOMA study.
    Krebs, Matthew G.
    Johnson, Melissa L.
    Cho, Byoung Chul
    Lee, Se-Hoon
    Kudgus-Lokken, Rachel
    Zemlickis, Donna
    Mitselos, Anna
    Berkay, Eileen
    Bauml, Joshua M.
    Knoblauch, Roland E.
    Hellemans, Peter
    Minchom, Anna
    CANCER RESEARCH, 2022, 82 (12)
  • [2] Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)
    Usmani, Saad Z.
    Nahi, Hareth
    Mateos, Maria-Victoria
    Lokhorst, Henk M.
    Chari, Ajai
    Kaufman, Jonathan L.
    Moreau, Philippe
    Oriol, Albert
    Plesner, Torben
    Benboubker, Lotfi
    Hellemans, Peter
    Masterson, Tara
    Clemens, Pamela L.
    Ahmadi, Tahamtan
    Liu, Kevin
    San-Miguel, Jesus
    BLOOD, 2016, 128 (22)
  • [3] Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study
    Chari, Ajai
    Nahi, Hareth
    Mateos, Maria-Victoria
    Lokhorst, Henk M.
    Kaufman, Jonathan L.
    Moreau, Philippe
    Oriol, Albert
    Plesner, Torben
    Benboubker, Lotfi
    Hellemans, Peter
    Masterson, Tara
    Clemens, Pamela L.
    Liu, Kevin
    San-Miguel, Jesus F.
    Usmani, Saad Z.
    BLOOD, 2017, 130
  • [4] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Andrea Wang-Gillam
    William Schelman
    Stacey Ukrainskyj
    Caly Chien
    Martha Gonzalez
    Zhao Yang
    Marek Kania
    Heather Yeckes-Rodin
    Investigational New Drugs, 2023, 41 (6) : 851 - 860
  • [5] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Wang-Gillam, Andrea
    Schelman, William
    Ukrainskyj, Stacey
    Chien, Caly
    Gonzalez, Martha
    Yang, Zhao
    Kania, Marek
    Yeckes-Rodin, Heather
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 851 - 860
  • [6] SUBCUTANEOUS DARATUMUMAB IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE 1B STUDY (PAVO)
    Mateos, M., V
    Chari, A.
    Nah, H.
    Lokhorst, H.
    Kaufman, J. L.
    Moreau, P.
    Oriol, A.
    Plesner, T.
    Benboubker, L.
    Hellemans, P.
    Masterson, T.
    Clemens, P. L.
    Liu, K.
    San-Miguel, J.
    Usmani, S. Z.
    HAEMATOLOGICA, 2018, 103 : 32 - 33
  • [7] A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
    Zonder, Jeffrey A.
    Mohrbacher, Ann F.
    Singhal, Seema
    van Rhee, Frits
    Bensinger, William I.
    Ding, Han
    Fry, John
    Afar, Daniel E. H.
    Singhal, Anil K.
    BLOOD, 2012, 120 (03) : 552 - 559
  • [8] A phase 1b, open-label, dose escalation and expansion study of demcizumab plus pembrolizumab in patients with locally advanced or metastatic solid tumors
    Johnson, Melissa
    Rasco, Drew
    Schneider, Brian
    Shu, Catherine
    Jotte, Robert
    Parmer, Hema
    Stagg, Robert
    Lopez, Juanita
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [9] A Phase 1, Open-Label, Dose Escalation Study of Intravenous Paricalcitol in Combination With Gemcitabine in Patients With Advanced Malignancies
    Fountzilas, Christos
    Javle, Milind
    Tan, Wei
    Ma, Yingyu
    Fetterly, Gerald
    Iyer, Renuka
    Johnson, Candace
    CANCER, 2018, 124 (19) : 3890 - 3899
  • [10] Vorolanib (CM082) in Chinese patients with advanced solid tumor: A phase 1, open-label, dose escalation study.
    Song, Yan
    Wang, Jinwan
    Zhou, Ai-Ping
    Zhang, Wen
    Liang, Chris
    Yang, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345